OVID - Ovid therapeutics Inc Stock Price, Fair Value and News

3.15USD-0.13 (-3.96%)Delayed

Market Summary

USD3.15-0.13

Delayed

-3.96%

OVID Stock Price

View Fullscreen

OVID RSI Chart

OVID Valuation

Market Cap

223.5M

Price/Earnings (Trailing)

-4.41

Price/Sales (Trailing)

777.87

EV/EBITDA

-3.81

Price/Free Cashflow

-4.43

OVID Price/Sales (Trailing)

OVID Profitability

EBT Margin

-17096.73%

Return on Equity

-64.75%

Return on Assets

-38.51%

Free Cashflow Yield

-22.57%

OVID Fundamentals

OVID Revenue

Revenue (TTM)

296.4K

Rev. Growth (Yr)

881.55%

Rev. Growth (Qtr)

45.3%

OVID Earnings

Earnings (TTM)

-50.7M

Earnings Growth (Yr)

12.4%

Earnings Growth (Qtr)

23.64%

Breaking Down OVID Revenue

Last 7 days

Last 30 days

1.3%

Last 90 days

-18.0%

Trailing 12 Months

-9.0%

How does OVID drawdown profile look like?

OVID Financial Health

Current Ratio

10.47

OVID Investor Care

Shares Dilution (1Y)

0.60%

Diluted EPS (TTM)

-0.73

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	850.6K	198.5K	296.4K	0
2022	167.0M	84.3M	42.9M	1.5M
2021	61.6M	110.5M	159.4M	208.4M
2020	0	0	0	12.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Ovid therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 18, 2024	levin jeremy m	bought	50,364	2.76	18,248	ceo
Feb 22, 2024	rona jeffrey a	acquired	-	-	28,125	cbfo
Feb 22, 2024	perone thomas michael	acquired	-	-	28,125	general counsel, secretary
Feb 22, 2024	tardio jason	acquired	-	-	28,125	chief operating officer
Dec 04, 2023	levin jeremy m	gifted	-	-	-1,146,550	ceo
Sep 12, 2022	tardio jason	sold	-37,289	2.15	-17,344	chief operating officer
Jul 01, 2022	takeda pharmaceutical co ltd	sold	-	-	-5,750,000	-
Jul 01, 2022	takeda pharmaceutical co ltd	acquired	-	-	5,750,000	-
Jul 14, 2021	rakhit amit	sold	-126,203	3.71	-34,017	president and cmo
Jul 14, 2021	rakhit amit	acquired	64,292	1.89	34,017	president and cmo

Which funds bought or sold OVID recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.92	-13,319	18,285	-%
May 16, 2024	JANE STREET GROUP, LLC	added	5.26	-482	163,419	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	reduced	-18.54	-323,187	1,091,500	0.02%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-65.77	-118,177	56,694	-%
May 15, 2024	OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC)	added	79.58	326,185	791,475	0.06%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	new	-	124,040	124,040	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	new	-	445,193	445,193	-%
May 15, 2024	PRELUDE CAPITAL MANAGEMENT, LLC	new	-	77,943	77,943	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	450	59,499	73,612	-%
May 15, 2024	EcoR1 Capital, LLC	unchanged	-	-1,039,960	18,658,100	0.47%

Are Funds Buying or Selling OVID?

Are funds buying OVID calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OVID

No. of Funds

Unveiling Ovid therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	madison avenue partners, lp	5.2%	3,648,509	SC 13G/A
Feb 14, 2024	levin jeremy m	9.4%	6,942,181	SC 13G/A
Feb 12, 2024	rubric capital management lp	7.52%	5,315,969	SC 13G/A
Jan 29, 2024	blackrock inc.	6.1%	4,319,918	SC 13G
Jul 31, 2023	madison avenue partners, lp	5.1%	3,609,054	SC 13G
Feb 14, 2023	levin jeremy m	10.0%	7,281,121	SC 13G/A
Feb 14, 2023	biotechnology value fund l p	5.2%	3,631,500	SC 13G/A
Feb 13, 2023	stonepine capital management, llc	0%	0	SC 13G/A
Feb 10, 2023	ecor1 capital, llc	8.7%	6,117,400	SC 13G/A
Feb 10, 2023	rubric capital management lp	9.69%	6,828,065	SC 13G

Recent SEC filings of Ovid therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	8-K	Current Report
May 14, 2024	S-8	Employee Benefits Plan
Apr 24, 2024	ARS	ARS
Apr 24, 2024	DEF 14A	DEF 14A
Apr 24, 2024	DEFA14A	DEFA14A
Mar 20, 2024	4	Insider Trading
Mar 08, 2024	10-K	Annual Report
Mar 08, 2024	8-K	Current Report
Feb 26, 2024	4	Insider Trading

Peers (Alternatives to Ovid therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Ovid therapeutics Inc News

Latest updates

Ovid therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Revenue	-	-	-	108,972	75,000	66,160	46,280	11,102	8,327	5,551	2,776	-	-	-	208,382,779	107,648,407	6,914,034
Operating Expenses	-4.2%	17,565,000	18,329,908	12,137,804	14,246,982	14,958,465	12,219,192	12,814,958	14,304,287	17,712,472	-	26,353,665	11,681,734	14,312,826	31,825,463	27,294,429	23,317,696
S&GA Expenses	-100.0%	-	7,688,024	6,805,213	8,248,216	8,343,748	6,662,985	7,631,705	8,257,617	9,880,203	-	8,264,051	6,764,341	6,629,158	15,576,554	10,410,643	7,442,401
R&D Expenses	-2.3%	10,397,000	10,641,884	5,332,591	5,998,766	6,614,717	5,556,207	5,183,253	6,046,670	7,832,269	-	18,089,614	4,917,393	7,683,668	16,248,909	16,883,786	15,875,295
EBITDA Margin	3.2%	-169	-174	-161	-244	-59.79	-35.69	-1.60	-0.81	-0.54	0.74	0.60	0.81	1.12	-	-	-
Income Taxes	-	-	-	-	-	-	-25,000	-	-	50,000	-	-349,714	-294,829	1,473,084	500,277	-	-
Earnings Before Taxes	23.7%	-11,694,000	-15,322,034	-11,252,386	-12,408,330	-13,356,209	-11,529,788	-11,967,771	-14,588,414	-16,058,056	-	-26,349,762	-11,679,077	-14,315,343	176,507,584	-22,029,501	-16,424,789
EBT Margin	3.2%	-170	-176	-163	-248	-60.47	-36.03	-1.61	-0.82	-0.54	0.74	0.60	0.81	1.12	-	-	-
Net Income	23.6%	-11,700,000	-15,322,034	-11,252,386	-12,408,330	-13,356,209	-11,504,788	-11,967,771	-14,588,414	-16,108,056	-	-26,000,048	-11,384,248	-15,788,427	176,007,307	-22,029,501	-16,424,789
Net Income Margin	3.2%	-170	-176	-163	-247	-60.44	-36.05	-1.60	-0.81	-0.55	0.74	0.59	0.80	1.10	-	-	-
Free Cashflow	-40.2%	-16,705,000	-11,913,706	-10,105,245	-11,707,797	-12,113,560	-9,295,671	-12,694,973	-14,328,508	-20,132,354	-12,160,462	-12,160,462	-10,894,066	-19,405,376	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-8.6%	132	144	125	136	143	155	165	177	191	195	207	218	237	76.00	92.00	45.00	62.00	81.00	41.00	55.00	67.00
Current Assets	-15.0%	93.00	110	92.00	102	120	131	140	156	170	190	205	216	237	75.00	90.00	44.00	61.00	80.00	39.00	54.00	63.00
Cash Equivalents	20.9%	33.00	27.00	57.00	72.00	63.00	45.00	60.00	75.00	169	190	202	212	233	72.00	87.00	41.00	27.00	42.00	38.00	47.00	55.00
Net PPE	-10.8%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-5.2%	53.00	56.00	24.00	26.00	22.00	23.00	23.00	25.00	26.00	15.00	10.00	11.00	16.00	32.00	28.00	15.00	10.00	11.00	11.00	9.00	9.00
Current Liabilities	-22.4%	9.00	11.00	9.00	10.00	7.00	7.00	-	-	-	15.00	10.00	11.00	16.00	22.00	18.00	15.00	10.00	11.00	10.00	9.00	8.00
Shareholder's Equity	-10.8%	78.00	88.00	101	111	121	132	142	152	165	180	197	207	221	44.00	64.00	30.00	51.00	70.00	30.00	45.00	57.00
Retained Earnings	-4.2%	-289	-277	-262	-251	-238	-225	-214	-202	-187	-171	-145	-133	-118	-294	-272	-255	-233	-213	-196	-179	-166
Additional Paid-In Capital	0.6%	368	366	364	362	360	358	356	354	352	351	342	341	339	338	336	286	285	283	226	225	224
Shares Outstanding	0.1%	71.00	71.00	71.00	71.00	70.00	70.00	70.00	70.00	70.00	70.00	67.00	67.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	191	-	-	-	125	-	-	-	217	-	-	-	294	-	-	-	26.00	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-40.2%	-16,686	-11,900	-10,100	-11,700	-12,100	-9,175	-12,676	-13,288	-20,086	-11,998	-10,872	-19,416	160,899	-14,509	-1,469	-17,193	-18,411	-16,888	-9,494	-11,841	-12,866
Share Based Compensation	10.0%	1,968	1,789	1,631	1,949	1,917	1,730	1,782	1,720	1,325	1,315	1,162	1,257	1,320	2,051	2,616	1,555	1,303	1,127	1,184	1,252	1,643
Cashflow From Investing	141.6%	20,188	-48,516	-4,359	20,066	30,229	-4,169	-1,960	-80,677	-1,076	-161	-64.03	-1,583	-11.51	-90.48	-38.30	30,941	3,836	-35,008	-18.58	4,995	-8.97
Cashflow From Financing	-99.2%	228	30,033	224	211	67.00	-43.60	82.00	110	33.00	109	549	116	130	-232	47,120	169	16.00	55,886	59.00	-391	30,986

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

OVID Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue	$ 148	$ 66
Operating expenses:
Research and development	10,397	6,615
General and administrative	7,168	8,344
Total operating expenses	17,565	14,958
Loss from operations	(17,417)	(14,892)
Other income (expense), net	5,723	1,536
Loss before provision for income taxes	(11,694)	(13,356)
Provision for income taxes	0	0
Net loss	$ (11,694)	$ (13,356)
Net loss per share, basic (in dollars per share)	$ (0.17)	$ (0.19)
Net loss per share, diluted (in dollars per share)	$ (0.17)	$ (0.19)
Weighted-average common shares outstanding, basic (in shares)	70,716,929	70,490,704
Weighted-average common shares outstanding, diluted (in shares)	70,716,929	70,490,704

OVID Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 30,772	$ 27,042
Marketable securities	59,487	78,792
Prepaid expenses and other current assets	2,911	3,764
Total current assets	93,170	109,598
Long-term equity investments	22,022	17,626
Restricted cash	1,931	1,931
Right-of-use asset, net	13,628	13,894
Property and equipment, net	686	769
Other noncurrent assets	174	210
Total assets	131,613	144,027
Current liabilities:
Accounts payable	3,596	3,703
Accrued expenses	4,039	6,525
Current portion, lease liability	1,268	1,246
Total current liabilities	8,903	11,474
Long-term liabilities:
Lease liability	14,430	14,756
Royalty monetization liability	30,000	30,000
Total liabilities	53,333	56,230
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; Series A convertible preferred stock, 10,000 shares designated, 1,250 shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value; 125,000,000 shares authorized; 70,783,961 and 70,691,992 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	71	71
Additional paid-in-capital	367,787	365,591
Accumulated other comprehensive (loss) income	(19)	1
Accumulated deficit	(289,560)	(277,866)
Total stockholders' equity	78,279	87,797
Total liabilities and stockholders' equity	$ 131,613	$ 144,027

About Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, currently under preclinical stage, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV825, currently under preclinical stage, which has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, currently under preclinical stage, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

CEO	Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir
WEBSITE	ovidrx.com
INDUSTRY	Biotechnology
EMPLOYEES	40

Ovid therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Ovid therapeutics Inc? What does OVID stand for in stocks?

OVID is the stock ticker symbol of Ovid therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ovid therapeutics Inc (OVID)?

As of Fri May 17 2024, market cap of Ovid therapeutics Inc is 223.48 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OVID stock?

You can check OVID's fair value in chart for subscribers.

What is the fair value of OVID stock?

You can check OVID's fair value in chart for subscribers. The fair value of Ovid therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ovid therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OVID so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ovid therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether OVID is over valued or under valued. Whether Ovid therapeutics Inc is cheap or expensive depends on the assumptions which impact Ovid therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OVID.

What is Ovid therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, OVID's PE ratio (Price to Earnings) is -4.41 and Price to Sales (PS) ratio is 777.87. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OVID PE ratio will change depending on the future growth rate expectations of investors.